Myriad Genetics Inc. (MYGN) Stock
Key stats
- Market cap
- $548.67M
- Price / Earnings ratio
- -4.2x
- EPS (TTM)
- -$1.35
- Volume
- Loading
- 52-week high
- $8.09
- 52-week low
- $2.74
Source: third-party data provider, as of November 13, 2026
Compare with MYGN
Recent news
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
MYGN
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
MYGN
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
MYGN
Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week?
Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week?
MYGNTechnical indicators
- RSI 14
- 55.20
- MACD 12/26/9
- 0.37
- EMA 9 of MACD
- 0.47
- MACD histogram
- -0.10
- SMA 50
- $4.65
- Price above SMA 50
- EMA 50
- $5.01
- Price above EMA 50
- SMA 200
- $4.61
- Price above SMA 200
- EMA 200
- $4.98
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.08 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
MYGN SHAREHOLDER ALERT: Myriad Genetics Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations
MYGNMYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
MYGN Investors Have Opportunity to Join Myriad Genetics, Inc. Fraud Investigation with SBS Law
MYGNMYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
MYGN Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Myriad Genetics (MYGN)
MYGNWhy Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week?
Why Did RBLX, HTZ, MYGN Stocks Plunge To 52-Week Lows Last Week?
MYGN
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
Myriad Genetics (MYGN) Reports Q2 Loss, Misses Revenue Estimates
MYGN
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
3 Promising Genomics Stocks to Add to Your Portfolio in 2026
MYGN
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
Is This the Right Time to Hold MYGN Stock in Your Portfolio?
MYGN
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
Myriad (MYGN) Soars 8.3%: Is Further Upside Left in the Stock?
MYGN
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
Should You Add Myriad Genetics Stock to Your Portfolio Right Now?
MYGN
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?
MYGNAbout Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Samraat S. Raha | President, CEO & Director | 1973 |
| Mr. Benjamin R. Wheeler | CFO & Principal Accounting Officer | 1984 |
| Mr. Mark S. Verratti | Chief Operating Officer | 1968 |
| Dr. Dale Muzzey Ph.D. | Chief Scientific Officer | 1980 |
| Mr. Paul J. Diaz J.D. | Consultant | 1962 |
| Mr. Raj Jampa | Chief Technology Officer | — |
| Mr. Matthew Scalo | Senior Vice President of Investor Relations | — |
| Ms. Jennifer L. Fox J.D. | Chief Legal Officer | 1973 |
| Dr. Patrick M. Burke Ph.D. | Executive Vice President of Corporate & Business Development | — |
| Ms. Shereen Solaiman | Chief People Officer | 1973 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 55.20
- MACD 12/26/9
- 0.37
- EMA 9 of MACD
- 0.47
- MACD histogram
- -0.10
- SMA 50
- $4.65
- Price above SMA 50
- EMA 50
- $5.01
- Price above EMA 50
- SMA 200
- $4.61
- Price above SMA 200
- EMA 200
- $4.98
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
6 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $2.00
- Average
- $5.23
- High
- $8.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -12.6 | +10.8 | ||||||||||
| 2022 | -6.1 | -6.1 | +7.2 | -20.8 | -9.2 | -4.7 | +41.6 | -14.0 | -14.8 | +5.9 | +15.8 | -28.7 |
| 2023 | +29.2 | -5.1 | +8.5 | -10.4 | +1.7 | +0.3 | -3.7 | -18.0 | -11.0 | +0.5 | +21.3 | -0.5 |
| 2024 | +12.6 | -3.1 | -3.9 | -8.7 | +16.9 | +9.4 | +16.7 | +2.6 | -0.3 | -18.8 | -9.6 | -17.9 |
| 2025 | -6.1 | -16.0 | -14.6 | -16.2 | -41.2 | +19.1 | -30.6 | +62.9 | +4.8 | +4.0 | -6.7 | -12.9 |
| 2026 | -8.5 | -15.7 | -10.2 | +3.5 | -17.3 | +33.4 | -52.3 | +6.6 | +35.5 | +56.4 | -2.2 |
